[24.06.14] Clinical Results of Terminal Colorectal Cancer Treatment...

Clinical results of MetiMedi Pharmaceuticals’ Anti-EGFR targeted treatment for advanced colorectal cancer, METI-101, have demonstrated excellent safety with minimal adverse effects.In addition, compared to the current standard therapy, cetuximab rechallenge, which shows a median overall survival (OS) of 8–9 months, METI-101 demonstrated superior efficacy with a median overall survival of 23.4 months, indicating an expected survival extension of more than 15 months.For further details, please refer to the attached article from Yakup News.View Full Article : https://www.yakup.com/news/index.html?mode=view&cat=12&nid=293558

2025.09.22

[22.08.24] Status of Clinical trials

The Phase 2 clinical trial of MetiMedi Pharmaceutical Co., Ltd.’s anticancer drug OMT-111 (Pre-filled Syringe Formulation) is progressing smoothly as planned, with the last patient currently under administration.Once the final patient dosing is completed, the Phase 2 trial will be concluded and the results will be analyzed and reported to the Ministry of Food and Drug Safety of Korea.In addition, MetiMedi plans to prepare a journal publication of the trial results and present them at international conferences, while also initiating global marketing activities targeting multinational pharmaceutical companies.Furthermore, OMT-111 has been developed into an oral enteric-coated capsule formulation, Meti-101, to improve patient convenience and broaden its potential applications.On April 21, 2022, the Phase 1b/2a clinical trial of Meti-101 was approved by the Ministry of Food and Drug Safety of the Republic of Korea, and on August 11, 2022, it received conditional IRB approval from Gachon University Gil Medical Center. Final approval is expected following submission of additional requested documents.Upon IRB approval, the clinical trial contract will be signed and the study will commence with a planned enrollment of 30 patients.

2025.09.22

[22.08.24] CID Patent Registration Status

MetiMedi Pharmaceutical Co., Ltd.’s CID (Chronic Inflammatory Disease) patent was divided into three separate applications in the United States, and patent examinations are currently ongoing. On August 25, 2020, MetiMedi’s patents for multiple sclerosis, age-related macular degeneration, and non-alcoholic steatohepatitis (NASH) passed review by the U.S.Patent Office and were successfully registered. Furthermore, on January 26, 2021, the U.S. Patent Office approved and registered MetiMedi’s patents for Alzheimer’s disease, Parkinson’s disease, atherosclerosis, and inflammatory bowel disease. MetiMedi is continuing efforts to secure additional patents for other chronic inflammatory diseases.

2025.09.22

[22.08.24] Formulation Patent Registration Status

On July 7, 2022, the formulation patent for the anticancer drug of MetiMedi Pharmaceutical Co., Ltd. was successfully registered in Mexico after passing examination by the Mexican Patent Office.As a result, MetiMedi’s anticancer drug formulation patent has been registered in two countries: the United States (registered on March 29, 2022) and Mexico.Currently, MetiMedi is in the process of further expanding its formulation patent in 13 countries, including those under the European Patent Convention (EPC), Taiwan, and Japan.

2025.09.22

[22.08.24] Main Anti-cancer Drug Patent Registration Status

On July 11, 2022, MetiMedi Pharmaceutical Co., Ltd.’s main patent for its anticancer drug was successfully registered in Japan after passing the patent examination by the Japan Patent Office.As a result, MetiMedi’s main anticancer drug patent has now been registered in a total of 55 countries, including the United States (2 cases), Japan, Korea, 34 member countries of the European Patent Convention (EPC), and 11 member countries of the Eurasian Patent Organization (EAPO).Currently, MetiMedi is in the process of further expanding its patent coverage in 18 additional countries, including China.

2025.09.22

[20.11.16] Phase 1 Clinical Trial Abstract and Poster Submission Co...

We have completed submitting the poster to the Korean Cancer Society. 

2025.09.22